Political turmoil at the Food and Drug Administration (FDA) resulted in a critically important treatment, of which 1.5 million patients in the U.S. rely on each year, getting pulled from the market. Patients (and the product's manufacturer) were facing a potentially frightening deadline, at the end of which patients would no longer be able to access the treatment they needed.
Utilizing a multifaceted, multiteam approach, TRP successfully cut through the noise to execute a crisis response campaign that involved around-the-clock intelligence gathering & monitoring, aggressive outreach to key policymakers — including the FDA, the White House, and key offices on Capitol Hill — as well as numerous grassroots patient advocacy efforts through our TRP Engage platform.
The win was secured when the FDA revised its posture toward this treatment and allowed it to stay on the market to the relief of everyone involved.
